Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 65 % of short-term debt in 2024; threshold 65 %.
Financials
Financial year 2024
NORDPHARMA from Brussel, company number BE0749928180, closed financial year 2024 with a result of € 79,630 after tax. For that financial year NORDPHARMA recorded revenue of € 1.4 million and equity of € 494,640. Compared with financial year 2023, the result moved from € 77,576 to € 79,630. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on November 1, 2025.
€ 494,640
▲ 6% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 79,630
▲ 3% vs 2023
Profit after tax over the fiscal year.
€ 103,945
▲ 23% vs 2023
Cash and bank balances on the last day of the fiscal year.
€ 50,000 paid out
63 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2024
2.8
▲ 0.3 vs 2023
Average over the fiscal year, from the social balance sheet.
€ 135,987
▲ 25% vs 2023
€ 48,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 7,246
▼ 13% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2024
€ 35,557
▼ 28% vs 2023
€ 14,547 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 7,426
▼ 87% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 40,745
▲ 22% vs 2023
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Revenue | € 1,690,070 | € 1,342,281 | € 1,284,880 | € 1,352,434 | ▲ 5% |
| Gross margin | € 258,033 | € 226,841 | € 289,447 | € 279,900 | ▼ 3% |
| Profit after taxes | € -2,092 | € 53,526 | € 77,576 | € 79,630 | ▲ 3% |
| Equity | € 417,908 | € 435,435 | € 465,011 | € 494,640 | ▲ 6% |
| Total debts | € 221,098 | € 342,169 | € 283,148 | € 289,712 | ▲ 2% |
| Cash | € 49,767 | € 88,980 | € 84,414 | € 103,945 | ▲ 23% |
| Land & buildings | € 268,333 | € 268,333 | € 261,667 | € 255,000 | ▼ 3% |
| Retained profit | € -2,092 | € 15,435 | € 45,011 | € 74,640 | ▲ 66% |
| Dividend | € 0 | € 36,000 | € 48,000 | € 50,000 | ▲ 4% |
| Bank debt | € 46,372 | € 104,165 | € 49,297 | € 35,557 | ▼ 28% |
| Balance sheet total | € 639,006 | € 777,603 | € 748,159 | € 784,352 | ▲ 5% |
| Employees (FTE) | 3.5 | 2.5 | 2.5 | 2.8 | ▲ 0.3 |
Key figures of NORDPHARMA, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to NORDPHARMA?
What happened at NORDPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 79,630 (▲ 3% vs 2023). filed late Source: NBB ↗
- New establishment in Brussel. KBO
- Start of the company according to the CBE. KBO
In short
From € 2,092 loss in 2021 to € 79,630 profit in 2024.
Paid € 23,674 in corporate taxes since 2021.
Best year ever: 2024, with € 79,630 profit.
On average € 100,000 of value added per employee in 2024.
A new publication or filing at NORDPHARMA? We notify you, reason included.
Follow NORDPHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Establishments
Establishment units
Physical locations of this company
Maria-Christinastraat 21
1020 Brussel
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0749.928.180
- VAT number
- BE 0749.928.180
- Registered office
- Maria-Christinastraat 21, 1020 Brussel
- Names & denominations
- NORDPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 7 July 2020
- Peppol
- Active · Active since 29 Jan 2026
- Activities · NACE
Detailhandel in farmaceutische producten